Expanding treatment options for metastatic prostate cancer

New England Journal of Medicine

Volumn 364, Issue 21, 2011, Pages 2055-2058

  Antonarakis, Emmanuel S ^a   Eisenberger, Mario A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ABIRATERONE ACETATE; AFLIBERCEPT; ATRASENTAN; CABAZITAXEL; CUSTIRSEN; DASATINIB; DOCETAXEL; IPILIMUMAB; KETOCONAZOLE; LENALIDOMIDE; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; TASQUINIMOD; ZIBOTENTAN;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG ACTIVITY; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; HUMAN; METASTASIS POTENTIAL; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RISK REDUCTION; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79957497548     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1102758     Document Type: Editorial

References (10)

1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004;22:2141-9. (Pubitemid 41095147)
2. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009;15:4792-8.
3. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
4. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-33. (Pubitemid 41095034)
5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. (Pubitemid 39315317)
6. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64. (Pubitemid 26185452)
7. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
8. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
9. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22.
10. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16-22.